Announcements
- Nexstim Oyj: Arvopaperimarkkinalain 9 luvun 10 §:n mukainen ilmoitus huomattavasta omistusosuudesta
- Nexstim Plc: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act
- Sisäpiiritieto: Nexstim Oyj ilmoittaa lisätietoja liittyen Magnus Medical, Inc.:n teknologian lisensointisopimukseen
- Insider Information: Nexstim Plc Provides Further Details on Technology License Agreement with Magnus Medical, Inc.
- Distributor Orders Nexstim NBS System 5 for European Hospital
- Insider Information: Nexstim Plc Announces Planned Alzheimer’s Collaboration with Sinaptica Therapeutics, Inc.
- Sisäpiiritieto: Nexstim Oyj tiedottaa suunnitellusta yhteistyöstä Sinaptica Therapeutics, Inc:n kanssa Alzheimerin taudin hoidon alalla
- Finnish Hospital Orders Nexstim NBS System 5
- Health Canada Approves Nexstim NBS 6 System for Treatment of MDD
- Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement for US Market
More ▼
Key statistics
As of last trade, Nexstim Oyj (5NX:FRA) traded at 2.95, 52.06% above the 52 week low of 1.94 set on Oct 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.95 |
---|---|
High | 2.95 |
Low | 2.95 |
Bid | 2.81 |
Offer | 3.09 |
Previous close | 3.04 |
Average volume | 0.00 |
---|---|
Shares outstanding | 6.77m |
Free float | 3.46m |
P/E (TTM) | -- |
Market cap | 21.65m EUR |
EPS (TTM) | -0.1956 EUR |
Data delayed at least 15 minutes, as of Jun 18 2024 08:22 BST.
More ▼